Puma Biotechnology (PBYI) EBITDA Margin (2017 - 2026)
Puma Biotechnology's (PBYI) quarterly EBITDA Margin came in at 8.54% in Q1 2026, down 1720.0% YoY from 0.53% in Q1 2025, and down 137.68% on a QoQ basis from 22.67% in Q4 2025.
Puma Biotechnology (PBYI) EBITDA Margin (2017 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 10 years of EBITDA Margin data on file, last reported at 8.54% in Q1 2026.
- Quarterly EBITDA Margin fell 1720.0% year-over-year to 8.54% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12.98% (down 303.0% YoY) and the FY2025 annual result came in at 16.33%, up 290.0% from the prior year.
- EBITDA Margin slipped to 8.54% in Q1 2026, from 22.67% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 27.41% in Q3 2024 to a low of 8.54% in Q1 2026.
- A 5-year average of 10.61% and a median of 11.43% in 2022 frame the typical range for EBITDA Margin.
- The widest YoY moves for EBITDA Margin: up 5142 bps in 2022, down 2216 bps in 2022.
- Tracing PBYI's EBITDA Margin over 5 years: stood at 11.43% in 2022, then surged by 79 bps to 20.5% in 2023, then grew by 10 bps to 22.62% in 2024, then gained by 0 bps to 22.67% in 2025, then slumped by 138 bps to 8.54% in 2026.
- The last three EBITDA Margin figures came in at 8.54% (Q1 2026), 22.67% (Q4 2025), and 17.57% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 13.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.42% |
| Mar 31, 2026 | -8.54% |
| Dec 31, 2025 | 22.67% |
| Sep 30, 2025 | 17.57% |
| Jun 30, 2025 | 12.66% |
| Mar 31, 2025 | 8.66% |
| Dec 31, 2024 | 22.62% |
| Sep 30, 2024 | 27.41% |
| Jun 30, 2024 | -4.63% |
| Mar 31, 2024 | -5.25% |
| Dec 31, 2023 | 20.50% |
| Sep 30, 2023 | 15.30% |
| Jun 30, 2023 | 8.96% |
| Mar 31, 2023 | 8.27% |
| Dec 31, 2022 | 11.43% |
| Sep 30, 2022 | 4.19% |
| Jun 30, 2022 | 20.26% |
| Mar 31, 2022 | -1.63% |
| Dec 31, 2021 | 12.34% |
| Sep 30, 2021 | -19.36% |